Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817459 | 0.87 | TLR8 (0.48) | TLR8 | |
| SCHEMBL3819939 | 0.84 | ADORA3 (0.40) | TLR8PGK1 | |
| SCHEMBL2906856 | 0.81 | TLR7 (0.34) | TLR8PGK1 | |
| SCHEMBL8507938 | 0.80 | TLR8 (0.34) | TLR8PGK1 | |
| SCHEMBL21295321 | 0.77 | KDM4E (0.31) | TLR8 | |
| SCHEMBL8676844 | 0.77 | PTPN11 (0.37) | — | |
| SCHEMBL5822570 | 0.77 | TLR7 (0.31) | — | |
| SCHEMBL2828998 | 0.75 | — | — | |
| SCHEMBL28928674 | 0.74 | CHUK (0.32) | — | |
| SCHEMBL4606082 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | claimed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | claimed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | claimed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | claimed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | claimed |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2003-04-17 | — | — | US | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| US-6414127-B1 | INCREASED AFFINITY TO COMPLEMENTARY OLIGONUCLEOTIDES; DNA SEQUENCING; MEDICAL DIAGNOSIS; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | claimed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | claimed |
| JP-2001522860-A | — | — | 2001-11-20 | — | — | JP | claimed |
| EP-1027364-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| US-6028183-A | Pyrimidine derivatives and oligonucleotides containing same | GILEAD SCIENCES, INC. (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | claimed |
| US-5817781-A | ENZYME INHIBITORS; INCREASED PENETRATION OF CELLS; DEACTIVATEPROTEIN SYNTHESIS, RNA, DNA | GILEAD SCIENCES, INC. (US) | 1998-10-06 | — | — | US | claimed |
| CN-106566855-B | Nucleic acid amplification using reversibly modified oligonucleotides | 苏州新海生物科技股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-106566855-A | Nucleic acid amplification using reversibly modified oligonucleotide | 毕万里 | 2017-04-19 | — | — | CN | disclosed |
| WO-1996040725-A1 | PHOSPHONIC ACID-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996001841-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | TLR8 4699/4885PGK1 2920/4885 |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | TLR8 4699/4885PGK1 2920/4885 |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | RBBP4, DDB1, DPYD | TLR8 4690/4885PGK1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.